Phase 2
Completed N=100
Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy
Source: ClinicalTrials.gov NCT01710345 ↗Enrolled (actual)
100
Serious AEs
2.0%
Results posted
Jan 2015
Primary outcomePrimary: SPID-12 — -5.65; 6.53; -7.12 units on a scale — p=0.742
Summary
This is a dose-finding study to determine if the sublingual administration of the Sufentanil NanoTab is safe and effective in the treatment of post-operative pain.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY SPID-12 |
-5.65; 6.53; -7.12 | 0.742 |
Eligibility Criteria
Inclusion Criteria
- patients scheduled for bunion surgery
Exclusion Criteria
- daily opioid use
- drug or alcohol abuse
- pregnant or breastfeeding women
Data sourced from ClinicalTrials.gov (NCT01710345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.